Thromboembolism and its Prevention
Pulmonary embolism is a serious hazard after accidents, after surgery and after various medical conditions. Until recently little could be done about it but the discovery of anticoagulants has changed the situation.
Since emboli begin as thrombi in the deep veins of the lower limbs or pelvis, their prevention is equivalent to the prevention of venous thrombi. Anticoagulant prophylaxis has to begin early, before venous stasis lets thrombi form and it must be continued until venous stasis and the danger of thrombosis has passed. Prophylaxis has epidemiological overtones; that is, many more patients have to be protected than would have developed embolism if left unprotected; moreover the drugs have risks and require much clinical and laboratory supervision.
Basis ofProphylaxis
The need for prevention was assessed in injured patients (Sevitt & Gallagher 1959 though the same basic arguments apply to all others: (1) Pulmonary embolism is frequent in those over the age of 40 years confined to bed after injury. It is the commonest single cause of death in the elderly injured.
(2) Necropsy dissection has shown frequent thrombosis in the deep veins of the lower limbs in injured patients. However, in most of them thrombosis had been without symptoms or signs.
(3) Half the cases of fatal pulmonary embolism occur in subjects with silent thrombosis; that is, embolism is not preceded by pain or swelling in a limb.
(4) The clinical signs of possibly diagnosable thrombosis are often slight or equivocal and easily overlooked in routine practice so that treatment is often late or not given.
If treatment is given only to those diagnosed as having thrombosis it follows that many cases of fatal (or nonfatal) embolism will continue to occur: hence the superiority of prophylaxis over treatment. Moreover, treatment may be unsuccessful, especially when diagnosis is delayed.
Frequency ofPulmonary Embolism
Clinical estimates err on the low side because pulmonary embolism is often difficult to diagnose and most cases found at necropsy have been unsuspected during life. Sudden collapse is only one of the syndromes which may oocur (Sevitt & Gallagher 1961 . The necropsy incidence of major pulmonary embolism at the Birmingham Accident Hospital before prophylactic measures were instituted was about 20% (Sevitt & Gallagher 1961) . Of the 104 cases of embolism 95 (91 %) studied at necropsy were in patients older than 50 years. This is important in selection of cases for anticoagulant prophylaxis because if they could be prevented the frequency of fatal embolism in the hospital would decrease by about 90 %.
Embolism was found in 49-60% of patients dying after a fractured femur or tibia and was the most common cause of death among them. It was frequent among those dying after a fractured pelvis (27%) or a fractured spine (14%) but less common in those with abdominal, thoracic or cerebral trauma (2-1 to 5 5 %) or burns (5.5 %).
The differences in frequency are largely derived from differences in the incidence of venous thrombosis which in turn largely depends on advancing age and duration of bed rest. Those with the highest rates of venous thrombosis have the highest rates of embolism. Those who die after a fracture of the lower limb or pelvis are mostly elderly; they remain inactive long enough for venous thrombosis to develop. Many who die because of head injuries, burns or other trauma are either young or die within a few days of injury when venous thrombosis is less common or less extensive when present. The group of patients with fractured hips is important because the injury is common, the population is ageing and they have a high rate of embolism. Half of the 104 Table 1 Summary of main results of the controlled trial of anticoagulant prophylaxis against thromboembolism in elderly patients with fractwred hips (see Sevitt & Gallagher 1959) (Sevitt & Gallagher 1961) . This is a conservative estimate because patients with pulmonary embolism were deliberately excluded. These thrombi are the source of pulmonary emboli and the most dangerous emboli come from the iliofemoral veins. Estimates of venous thrombosis among medical and surgical necropsies by other workers range from 44 to 60 % (Neumann 1938 , Hunter et al. 1945 , Gibbs 1957 . Bilateral thrombi are almost twice as common as unilateral thrombi even when only one leg or thigh is fractured or when clinical signs of thrombosis had been confined to one limb.
Analysis of our data showed a very frequent thrombosis related to advancing age and increasing survival period (bed rest). The rate of thrombosis was particularly high in those over 40 years of age who survived longer than three days of bed rest. This was important for the selection of cases for routine prophylaxis.
Clinical and Silent Thrombosis
The diagnosis of deep vein thrombosis need not be elaborated here except to say that unilateral swelling beginning in or restricted to the calf is the most reliable sign and that pain, tightness or tenderness in the calf are valuable but are often absent. Diagnosis has often to be made on minor swelling and this naturally depends on clinical watchfulness.
The incidence of clinical thrombosis is higher than is generally believed but is only a fraction of that seen at necropsy. Clinical thrombosis was found in about one in 3 patients with a fracture of the hip while dissections at necropsy revealed thrombi in 75 %. A similar clinical incidence was found in the survivors and those who died so that it is reasonable to conclude that only about onethird of the survivors with thrombi developed clinical signs of thrombosis. Thrombosis was a silent process in the remaining two-thirds of the cases.
Unheralded Embolism and Silent Thrombosis
The frequency of silent thrombosis explains why embolism is so infrequently preceded by symptoms or signs of venous thrombosis. In less than half the cases with embolism at necropsy had there been clinical evidence of thrombosis. About half the episodes of embolism are unheralded by signs referable to the limbs.
A Controlled Trial That prophylaxis with an anticoagulant drug does prevent venous thrombosis and pulmonary embolism was established by a controlled clinicopathological trial among high-risk elderly patients with fractured hips (Sevitt & Gallagher 1959 ). They have a high incidence of venous thrombosis and embolism; they are a homogeneous group and their relatively high fatality rate provided the opportunity to dissect the lower venous tree and pulmonary arteries, giving unequivocal evidence of thrombosis and embolism or their absence. One hundred and fifty patients were given phenindione and 150 were not (control series). Phenindione therapy was begun soon after admission to hospital and was generally continued until satisfactory mobility was restored. Therapy was controlled by the one-stage plasma prothrombin time aimed to be prolonged to between two and three times normal. Such prophylaxis was found practical and safe and the fractures were pinned or nailed without significant hemorrhage.
The results, summarized in Table 1 , were clear cut. Embolism did not occur in any patient under the current influence of phenindione but, in the control series, embolism developed in 18 % of the patients and fatal embolism in 10%. Two cases of fatal embolism and one of minor embolism did occur in the phenindione series but were in patients in whom therapy had been stopped. Necropsy dissection for deep vein thrombi clinched the trial. In most of the phenindione series reaching necropsy the whole of the lower venous tree was completely free of thrombi whilst significant or extensive thrombosis was found in most ofthe control necropsies.
It was concluded that oral anticoagulant therapy does prevent thrombosis in deep veins and eliminates the risk of pulmonary embolismprovided that the drug is given early, for sufficient time and under laboratory supervision for control of dosage.
Other workers have confirmed the efficacy and safety of oral anticoagulant drugs (both coumarin and indanedione groups) in preventing venous thrombosis and pulmonary embolism in the highrisk elderly subjects with fractured hips (Eskeland 1962 , Fagan 1964 , McQuillan 1964 , Borgstrom et al. 1965 , Salzman et al. 1966 , in patients immobilized with other fractures (Neu et al. 1965) , in gynecological and obstetrical surgery (Chalmers et al. 1960 , Turnbull 1961 , general orthopedic surgery (Tubiana & Duparc 1961) as well as special hip operations (Tubiana & Duparc 1961 , Mayer & Sarkar 1964 , Harris et al. 1967 , and in general surgery (Dick et al. 1959 , Greep 1961 , Belding 1965 .
Routine Prophylaxis after Injury in the Birmingham Accident Hospital The implications of our trial have gone beyond the narrow group of elderly patients with fractured hips. Prophylaxis is now directed to those particularly at risk of venous thrombosis and embolism, that is those over the age of 40 years about to undergo a period of bedrest for longer than three days after injury or surgery and in whom anticoagulant therapy is not otherwise contraindicated. Prophylaxis with phenindione is instituted from the day of admission or the next day in all patients over 40 years with a fractured neck of femur, other fractures of the femur, with a fractured tibia, ankle or foot, severe bruises, lacerations, burns less than 15 % body area, with orthopw,dic conditions or admitted for planned surgery. Younger obese patients or others considered to be a special risk are also included. Patients with a fractured pelvis or with fractured ribs without visceral damage are also given phenindione from soon after admission. Limb surgery (pinning, nailing, plating, open reduction of fractures) is frequent and is carried out under anticoagulant activity without additional operative bleeding in the great majority. Therapy is continued until the patient is reasonably mobile and for about a week afterwards, that is during the entire period of venous stasis. This means not only the periods of bedrest and sitting out of bed but until a degree of independent mobility and ambulation is achieved: this is a matter for clinical judgment. This practice usually means therapy for three to six weeks but sometimes it is continued for months and even after discharge from hospital. Patients with a serious head injury, chest injury, abdominal injury, spinal injury or extensive burns are excluded from early prophylaxis because, if extra bleeding should occur, it would be attributed to the therapy.
Delayed prophylaxis is carried out in some of these patients, that is therapy is begun several days after admission at a time when the early dangers of hemorrhage have passed and early surgery is over. Contraindications are recent melmna, haematemesis or hmmoptysis, gastric, duodenal or other bowel ulceration and hemorrhagic diathesis. The possibility of silent peptic ulceration with its possible severe himorrhage has to be continually borne in mind.
Therapy is controlled by prothrombin time using a sensitive human brain thromboplastin; the aim of therapy is to reduce plasma prothrombin activity to between 18 % and 25% of normal, based on a saline dilution calibration curve of normal plasma. This range was shown to have an effective antithrombotic effect and to reduce hemorrhagic complications, (Sevitt & Innes 1964) . Control by the thrombotest-reagent was also effective provided that the plasma-clotting activity was reduced to below 10% of normal, not to below 25% as advocated by the manufacturers (Sevitt & Innes 1964) . The feces are examined for meliena after admission and htmoglobin estimations are done at least once a week.
Results ofRoutine Prophylaxis
Our experience in routine practice since 1960 has confirmed the beneficial results of the earlier controlled trial of prophylaxis. Between 500 and 600 patients are given routine prophylaxis annually in the hospital and about 40% of these are the highrisk elderly subjects with fractured hips. Analysis of the success or failure ofprophylaxis is based on a continuing study of those who reach necropsy, by assessing the absence or presence of deep vein thrombi and lung emboli. During 1963 and (Table 2) 409 patients with fractured hips received prophylaxis and 50 of them died (12-2%); 39 reached necropsy and major lung embolism was found in only 3 of them. Embolism, however, was absent in those whose prophylaxis was begun * Failures due to delay in prophylaxis or stopping drug therapy too soon * Early uninterrupted prophylaxis only. Failures accounted for by method of control oftherapy, especially thrombotest at 15 % to 25 % activity early and was continued until death; the 3 cases of embolism were among a small group in whom therapy had been discontinued days or weeks before death or in whom the institution of therapy had been delayed. Table 3 compares progress over the years among the comparable groups of patients with fractured hips. Without prophylaxis (1947-57) major embolism was found in 46 % of necropsies and significant or extensive deep vein thrombi in 83 % of those without embolism. Similar results were found in the control series of the controlled prophylactic (1957-9) trial. These compare with a necropsy frequency of major embolism of only 9 5 % in the phenindione series of the trial, of 14-7 % during 1960-3 when a special study of therapy-control (Sevitt & Innes 1964 ) was carried out, and the figure of 7 7% in 1963-4. More recent analyses (1965 and 1966) are under way but the results are similar. The frequency of deep vein thrombosis has also been greatly reduced. In other words major embolism among this highly susceptible group has been lowered by over 80% as judged by necropsy material. This, of course, excludes the many patients who survived who otherwise might have died of embolism, the prevention of nonfatal embolism, and is a minimal estimate of improvement. Table 4 better indicates the degree of success and the number of lives probably saved by prophylaxis. Results in the fractured hip series are compared again but fatality rates are now included. These were 28 % among the control series, 16X7 % in the phenindione series, and 12.2% during 1963-4. This suggests that for every 100 patients with fractured hips now admitted to hospital, between 9 and 16 are saved from death by this prophylaxis. Since the necropsy rates were high, most of the difference in the fatality rates can be accounted for by the considerable reduction in the overall frequency of major embolism, from 10% among the 1957-9 controls to 1-3% and 0 7 % respectively in those given prophylaxis.
On the debit side should be placed 1 or 2 deaths in which anticoagulant therapy may have been implicated: indirectly in one subject through septicama following bacterial infection of a surgical wound haematoma and possibly directly in another who died after only three days of therapy but showed tarry hemorrhage in the small bowel from a recently bleeding chronic duodenal ulcer. There had been no clinical evidence of this. On the debit side must also be placed hemorrhagic incidents in about 5 % of other patients, some with occult blood in the frces and others with surgical wound hmmatomasalthough both these are known without anticoagulant therapy.
Surgical andMedical Cases
Our experience and that of others has shown that routine prophylaxis against thrombosis and embolism is safe and effective in general, gynecological and orthopedic surgery (Chalmers et al. 1960 , Turnbull 1961 , Tubiana & Duparc 1961 , Mayer & Sarkar 1964 , Harris et al. 1967 , Dick et al. 1959 , Greep 1961 , Belding 1965 . Some workers begin drug therapy on the second or third day after operation but this seems late considering that two days are required for effective drug action. Others begin on the first postoperative day. Ideally prophylaxis should begin before surgery and as soon as the patient is put to bed provided that the surgeon concerned is satisfied that there is no special risk of added bleeding. Therapy will generally be shorter in patients requiring general and gynmcological surgery than among accident and orthopedic cases because independent mobility is achieved sooner. Seven to fourteen days of therapy may be sufficient in most of them.
Surgeons are naturally concerned about the risk of operative and post-operative himorrhage but courage is gained with experience and there is now sufficient evidence that there is little or no added risk of operative bleeding even when thoracic, abdominal, prostatic and other major surgery is done under anticoagulant therapy at therapeutic levels of prothrombin time.
It is now common practice to institute anticoagulant therapy in patients with myocardial infarction in an attempt to prevent further coronary thrombosis. Short term therapy (for about four to six weeks) does reduce the fatality rate but much if not all the benefit seems due to preventing pulmonary embolism rather than a recurrence of coronary occlusion (Gilchrist & Tulloch 1956 , Honey & Truelove 1957 , Richards 1962 . Similar reasoning would suggest that prophylaxis by oral anticoagulant drugs would be of benefit in many other medical patients exposed to the dangers of deep vein thrombosis from venous stasis. Indeed the incidence of pulmonary embolism and mortality in congestive cardiac failure is reduced by anticoagulant therapy (Anderson & Hull 1950 , Honey & Truelove 1957 . Anticoagulant drugs have been used in acute cerebrovascular episodes, acute embolism or thrombosis in peripheral arteries, mesenteric artery thrombosis, retinal vessel occlusion and other arterial diseases. Whatever merits or otherwise they have for these conditions, there is evidence that some lives can be saved by preventing the complication of pulmonary embolism. Obviously proper studies, preferably controlled clinicopathological trials, are required to define the indications and limitations of therapy in these and other medical states.
